IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 151-175 out of 1380.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

Public Release: 2-Aug-2016
Clinical Cancer Research
Stem cells may speed up screening of drugs for rare cancers
Researchers at the Johns Hopkins Kimmel Cancer Center say they have developed a system that uses transformed human stem cells to speed up screening of existing drugs that might work against rare brain and other cancers.
St. Baldrick's Foundation, Hyundai Hope on Wheels, Giant Food's Pediatric Cancer Research Fund, Spencer Grace Foundation, Deming Family, Children's Brain Tumor Foundation, National Cancer Institute, National Institutes of Health

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 2-Aug-2016
PLOS Medicine
More accurate prostate cancer prognosis
Men diagnosed with prostate cancer can be provided with a more accurate estimate of their risk of death from the disease, and treatment planned accordingly, according to a Research Article published by Vincent J. Gnanapragasam, of the University of Cambridge, Cambridge, UK, and colleagues in PLOS Medicine.

Contact: PLOS Medicine
medicinepress@plos.org
PLOS

Public Release: 2-Aug-2016
Nature
T cell revival through PD-1: Clues for cancer immunotherapy
Scientists from Emory Vaccine Center show what molecular features distinguish the subset of exhausted T cells that can be re-energized, when mice with chronic viral infections are treated with PD-1-blocking agents. Useful information for optimizing cancer immunotherapy and combinations with other drugs.
NIH/National Institute of Allergy and Infectious Diseases

Contact: Quinn Eastman
qeastma@emory.edu
404-727-7829
Emory Health Sciences

Public Release: 2-Aug-2016
Immunity
Cancer checkpoint drug target governs metabolic changes in exhausted T cells
Reprogramming of the molecular pathways underlying normal metabolism is essential for T cell infection-fighting and for the immune system to form 'memory' of the microbes it has encountered. But exactly how metabolism in exhausted T cells is maintained in chronic infections and cancer is missing. A new study suggests that tweaking metabolic steps in combination with checkpoint blockade drugs may improve some cancer therapies.
German Research Foundation, Robertson Foundation/Cancer Research Institute Irvington Fellowship, Philadelphia Foundation Brody Family Medical Trust Fund fellowship, National Institutes of Health, Parker Institute for Cancer Immunotherapy

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 2-Aug-2016
Molecular Biology and Evolution
The great evolutionary smoke out: An advantage for modern humans?
A genetic mutation may have helped modern humans adapt to smoke exposure from fires and perhaps sparked an evolutionary advantage over Neandertals, according to a team of Penn State researchers.
National Institutes of Health

Contact: Joe Caspermeyer
MBEpress@gmail.com
480-258-8972
Molecular Biology and Evolution (Oxford University Press)

Public Release: 2-Aug-2016
Immunity
'Starving' immune cell discovery points to cancer immunotherapy-boosting strategies
The microenvironment that supports a cancerous tumor also starves the immune cells that the body sends in to destroy the cancer, University of Pittsburgh Cancer Institute scientists revealed in a discovery that holds the potential to significantly boost the performance of breakthrough immunotherapy drugs.
Sidney Kimmel Foundation for Cancer Research, National Institutes of Health

Contact: Allison Hydzik
HydzikAM@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 2-Aug-2016
Significance
Experts assess changes to breast cancer screening recommendations
A new article discusses the evidentiary support for the recent changes made by the American Cancer Society in its recommendations for breast cancer screening. In addition to modifying the suggested ages for annual and biannual mammography, the new recommendations also focus on patient preference in decision making.

Contact: Penny Smith
sciencenewsroom@wiley.com
Wiley

Public Release: 1-Aug-2016
American Journal of Roentgenology
Primary liver carcinoma may be misclassified based solely on major imaging features
A study released in the July 2016 issue of the American Journal of Roentgenology found that biphenotypic primary liver carcinoma may be misclassified as hepatocellular carcinoma.

Contact: Kimberly Coghill
kcoghill@arrs.org
703-858-4332
American Roentgen Ray Society

Public Release: 1-Aug-2016
EBioMedicine
Over 750 biomarkers identified as potentials for early cancer screening test
Researchers have identified 788 biomarkers in blood that could be used to develop an early stage cancer screening test for the general population.

Contact: Jo Kelly
jo@campuspr.co.uk
44-798-026-7756
University of Sheffield

Public Release: 1-Aug-2016
Annals of Internal Medicine
Nonfunctional adrenal tumors significantly increase risk for diabetes
Patients with nonfunctional adrenal tumors have a significantly higher risk for diabetes compared to patients without adrenal tumors. These findings suggest that a classification of 'nonfunctional' may not adequately describe the continuum of hormone secretion and metabolic risk associated with benign adrenal tumors.

Contact: Cara Graeff
cgraeff@acponline.org
215-351-2513
American College of Physicians

Public Release: 1-Aug-2016
Nature Nanotechnology
Synthetic vaccine particles immune tolerance mechanism published in Nature Nanotechnology
Preclinical studies show that Selecta Biosciences' proprietary immune therapies use a targeted mechanism of action to improve the efficacy and safety of biologic therapeutics and to address autoimmune diseases and allergies. The company is developing targeted antigen-specific immune therapies for rare and serious diseases. The data in Nature Nanotechnology support Selecta's lead clinical program, showing Selecta's SVP-Rapamycin induces antigen-specific immune tolerance and prevents the formation of anti-drug antibodies to biologic drugs, including pegsiticase (gout) and adalimumab (rheumatoid arthritis).
Selecta Biosciences, Inc.

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
845-635-9828
The Yates Network

Public Release: 1-Aug-2016
Nature Structural and Molecular Biology
DNA's dynamic nature makes it well-suited to serve as the blueprint of life
A new study could explain why DNA and not RNA, its older chemical cousin, is the repository of genetic information. The DNA double helix is a more forgiving molecule that can contort itself into different shapes to absorb chemical damage to the basic building blocks -- A, G, C and T -- of genetic code. In contrast, when RNA is in the form of a double helix, it is so rigid that rather than accommodating damaged bases, it falls apart.
National Institutes of Health, Austrian Science Fund

Contact: Robin Ann Smith
ras10@duke.edu
919-681-8057
Duke University

Public Release: 1-Aug-2016
Plastic and Reconstructive Surgery
Racial disparity in breast reconstruction? African-American women more likely to undergo autologous reconstruction
African-American women undergoing mastectomy for breast cancer are more likely than white women to undergo autologous breast reconstruction using their own tissue, rather than implant-based reconstruction, reports a study in the August issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Public Release: 1-Aug-2016
Journal of Urology
No link found between erectile dysfunction drugs and risk of prostate cancer
While some previous studies have indicated that taking erectile dysfunction drugs may reduce the likelihood of developing prostate cancer, new research published in The Journal of Urology found that these drugs do not play a role in preventing prostate cancer.

Contact: Eileen Leahy
jumedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 1-Aug-2016
EBioMedicine
One of the most common viruses in humans may promote breast cancer development
New research reveals that infection with the Epstein-Barr virus may put some women at increased risk for developing breast cancer. The findings, published online in the July issue of the journal EBioMedicine, may have important implications for breast cancer screening and prevention.
AVON Foundation, National Institutes of Health, University Cancer Research Fund

Contact: Jennifer Kritz
jkritz@bidmc.harvard.edu
617-667-7301
Beth Israel Deaconess Medical Center

Public Release: 1-Aug-2016
Annals of Internal Medicine
Patients with non-functional adrenal tumors at increased risk of diabetes
Investigators from Brigham and Women's Hospital have found that 'non-functional' adrenal tumors can increase a person's risk of developing type 2 diabetes.
NIH/National Institute of Diabetes and Digestive and Kidney Disease, Doris Duke Charitable Foundation, NIH/National Heart, Lung, and Blood Institute

Contact: Haley Bridger
hbridger@partners.org
617-525-6383
Brigham and Women's Hospital

Public Release: 1-Aug-2016
Cell Reports
UCI scientists identify a new approach for treating skin cancer
Using new and innovative immune-therapeutic approaches to silence 'don't eat me' signaling proteins recognized by specialized cells of the immune system, University of California, Irvine molecular biologists and their colleagues have identified an effective way to combat metastatic melanoma.
National Institutes of Health, Melanoma Research Alliance Young Investigator Award, J.M. Nicolay Melanoma Foundation, Virginia and D.K. Ludwig Fund for Cancer Research

Contact: Rahasson Ager
rager@uci.edu
949-824-6282
University of California - Irvine

Public Release: 1-Aug-2016
Journal of Experimental Medicine
New study finds CD4 T-Cell and Blimp-1 protein critical to toxoplasmosis regulation
Researchers from the George Washington University published in the Journal of Experimental Medicine finding a way to regulate chronic toxoplasmosis, one of the most common parasitic diseases worldwide. This research also has important implications for cancer.
National Institutes for Health

Contact: Lisa Anderson
lisama2@gwu.edu
202-994-3121
George Washington University

Public Release: 29-Jul-2016
Nature Materials
Triple-therapy patch delivers local treatment, prevents recurrence in colon cancer model
Investigators at Brigham and Women's Hospital have developed a hydrogel patch that can adhere to tumors in a preclinical model of colon cancer, delivering a local, combination treatment as the elastic gel breaks down over time.
National Institutes of Health, Koch Institute, NIH/National Cancer Institute, NIH/National Institute of Environmental Health Sciences, NIH/National Cancer Institute, National Science Foundation

Contact: Haley Bridger
hbridger@partners.org
617-525-6383
Brigham and Women's Hospital

Public Release: 29-Jul-2016
PLOS ONE
Krüppel-like factor 12 promotes colorectal cancer via early growth response protein 1
Medical University of South Carolina investigators report preclinical research showing that Krüppel-like factor 12 promotes colorectal cancer cell growth by activating early growth response protein 1, in the July 2016 issue of PLOS One. Data also reveal that levels of KLF12 and EGR1 correlate synergistically with a poor CRC prognosis. Results indicate that KLF12 plays an important role in CRC progression and provides a potential novel prognostic marker and therapeutic target.

Contact: Allison Leggett
leggett@musc.edu
843-792-5414
Medical University of South Carolina

Public Release: 29-Jul-2016
Cell Cycle
Pathway signatures in lung and liver fibrosis and glaucoma may play a role in aging
Scientists utilized the new software tool, Regeneration Intelligence, to evaluate the perturbation status of signaling pathways. The new system aimed to identify robust biomarkers of fibrotic disease and develop effective targeted therapies.

Contact: Qingsong Zhu
zhu@insilicomedicine.com
443-451-7212
InSilico Medicine, Inc.

Public Release: 28-Jul-2016
Clinical Cancer Research
T-cells can be directed to treat a variety of ovarian cancers
Scientists at The Wistar Institute have discovered a receptor-protein that is expressed on the surface of different types of ovarian tumor cells, including clear cell and mucinous ovarian tumors, two of the most aggressive subtypes of the disease. The protein is not found on non-ovarian healthy tissues in adult women, meaning that this protein could represent a highly specific therapeutic target in a range of ovarian tumors.
National Institutes of Health

Contact: Ben Leach
bleach@wistar.org
215-495-6800
The Wistar Institute

Public Release: 28-Jul-2016
Science Advances
Pitt researchers solve mystery on how regenerative medicine works
Researchers identify mechanism by which bioscaffolds used in regenerative medicine influence cellular behavior, a question that has remained unanswered since the technology was first developed several decades ago.

Contact: Lawerence Synett
SynettL@upmc.edu
412-647-9816
University of Pittsburgh Schools of the Health Sciences

Public Release: 28-Jul-2016
Cell Reports
Scientists discover new therapeutic target for lung cancer driven by KRAS
UT Southwestern Medical Center researchers have identified a new way to target lung cancer through the KRAS gene, one of the most commonly mutated genes in human cancer and one researchers have so far had difficulty targeting successfully.

Contact: Lori Sundeen Soderbergh
lori.soderbergh@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 28-Jul-2016
Plastic and Reconstructive Surgery
Insurance, distance to care can be barriers to breast reconstruction
Researchers say breast reconstruction can help with self-esteem, sexuality and body image after mastectomy. But a University of North Carolina Lineberger Comprehensive Cancer Center study has found that insurance type and distance to a plastic surgeon's office can be barriers to the procedure.

Contact: Laura Oleniacz
laura_oleniacz@med.unc.edu
919-445-4219
UNC Lineberger Comprehensive Cancer Center

Showing releases 151-175 out of 1380.

<< < 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 > >>

  Search News Releases

     

 

EurekAlert!